中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
机构
采集方式
内容类型
发表日期
学科主题
筛选

浏览/检索结果: 共10条，第1-10条 帮助

条数/页： 排序方式：
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML) 期刊论文  OAI收割
EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 卷号: 897
作者:  Lu, Tingting;  Cao, Jiangyan;  Zou, Fengming;  Li, Xixiang;  Wang, Aoli
  |  收藏  |  浏览/下载：39/0  |  提交时间：2021/04/26
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) 期刊论文  OAI收割
CANCER BIOLOGY & THERAPY, 2019, 卷号: 20, 期号: 6, 页码: 877-885
作者:  Wu, Jiaxin;  Wang, Aoli;  Li, Xixiang;  Chen, Cheng;  Qi, Ziping
  |  收藏  |  浏览/下载：76/0  |  提交时间：2019/11/27
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia 期刊论文  OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 160, 页码: 61-81
作者:  Liu, Xuesong;  Wang, Beilei;  Chen, Cheng;  Jiang, Zongru;  Hu, Chen
  |  收藏  |  浏览/下载：40/0  |  提交时间：2019/01/11
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFR alpha kinase inhibitor for PDGFR alpha driving chronic eosinophilic leukemia 期刊论文  OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 150, 期号: 无, 页码: 366-384
作者:  Wang, Qiang;  Liu, Feiyang;  Qi, Shuang;  Qi, Ziping;  Yan, Xiao-E.
  |  收藏  |  浏览/下载：62/0  |  提交时间：2019/06/10
Discovery of 4-Methyl-N-(44(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-y1)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding 期刊论文  OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 1, 页码: 273-289
作者:  Wang, Qiang;  Liu, Feiyang;  Wang, Beilei;  Zou, Fengming;  Qi, Ziping
  |  收藏  |  浏览/下载：29/0  |  提交时间：2018/07/04
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML) 期刊论文  OAI收割
ONCOTARGET, 2016, 卷号: 7, 期号: 29, 页码: 45562-45574
作者:  Liu, Feiyang;  Wang, Beilei;  Wang, Qiang;  Qi, Ziping;  Chen, Cheng
收藏  |  浏览/下载：38/0  |  提交时间：2017/11/21
Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells 期刊论文  OAI收割
CLINICAL CANCER RESEARCH, 2015, 卷号: 21, 期号: 4, 页码: 833-843
作者:  Wu, Lixian;  Yu, Jing;  Chen, Ruijia;  Liu, Yang
  |  收藏  |  浏览/下载：37/0  |  提交时间：2019/01/08
Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro 期刊论文  OAI收割
ACTA PHARMACOLOGICA SINICA, 2014, 卷号: 35, 期号: 3, 页码: 401-409
作者:  Wu, Li-xian;  Wu, Ying;  Chen, Rui-jia;  Liu, Yang;  Huang, Li-sen
  |  收藏  |  浏览/下载：20/0  |  提交时间：2019/01/08
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants 期刊论文  OAI收割
CANCER SCIENCE, 2014, 卷号: 105, 期号: 1, 页码: 117-125
作者:  Zhao, Jie;  Quan, Haitian;  Xu, Yongping;  Kong, Xiangqian;  Jin, Lu
  |  收藏  |  浏览/下载：26/0  |  提交时间：2019/01/08
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine(790) -> Methionine(790) Mutant 期刊论文  OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 卷号: 55, 期号: 6, 页码: 2711-2723
作者:  Chang, Shaohua;  Zhang, Lianwen;  Xu, Shilin;  Luo, Jinfeng;  Lu, Xiaoyun
  |  收藏  |  浏览/下载：17/0  |  提交时间：2019/01/08